protein

Recombinant Collagen Type I Alpha 2 (COL1a2)

MBS2029410

0.01 mg

140 USD

Recombinant Protein

Recombinant Collagen Type I Alpha 2 (COL1a2)

[Collagen Type I Alpha 2]

[collagen type I alpha 2, partial; Collagen alpha-2(I) chain; collagen alpha-2(I) chain; collagen, type I, alpha 2; Alpha-2 type I collagen]

[COL1a2]

[COL1A2; COL1A2; OI4]

CO1A2_HUMAN

E Coli

>97%

100mMNaHCO3, 500mMNaCl, pH8.3, containing 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.

Original Concentration: 200 ug/mL

Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months. Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. The loss of this protein is less than 5% within the expiration date under appropriate storage condition.

Positive Control; Immunogen; SDS-PAGE; Western Blot(WB). (May be suitable for use in other assays to be determined by the end user.)

Sequence Information

SDS-Page

Organism Species: Homo sapiens (Human). Source: Prokaryotic expression. Residues: Val1103~Lys1366. Tags: N-terminal His Tag . Subcellular Location: Secreted, Extracellular matrix. Traits: Freeze-dried powder

Predicted isoelectric point: 5.4. Predicted Molecular Mass: 33.4kDa. Accurate Molecular Mass: 33kDa as determined by SDS-PAGE reducing conditions. Reconstitution: Reconstitute in 100mM NaHCO3, 500mM NaCl (pH8.3) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

124265168

ABM98097.1

Amoebiasis Pathway (167324); Amoebiasis Pathway (167191); Assembly Of Collagen Fibrils And Other Multimeric Structures Pathway (1270247); Binding And Uptake Of Ligands By Scavenger Receptors Pathway (1269897); C-MYB Transcription Factor Network Pathway (138073); Collagen Biosynthesis And Modifying Enzymes Pathway (1270246); Collagen Formation Pathway (1270245); ECM-receptor Interaction Pathway (83068); ECM-receptor Interaction Pathway (479); Endothelins Pathway (137958)

This gene encodes the pro-alpha2 chain of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIB, recessive Ehlers-Danlos syndrome Classical type, idiopathic osteoporosis, and atypical Marfan syndrome. Symptoms associated with mutations in this gene, however, tend to be less severe than mutations in the gene for the alpha1 chain of type I collagen (COL1A1) reflecting the different role of alpha2 chains in matrix integrity. Three transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish, Feb 2008]

COL1A2: Type I collagen is a member of group I collagen (fibrillar forming collagen). Defects in COL1A2 are the cause of Ehlers-Danlos syndrome type 7B (EDS7B). EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS7B is marked by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations. Defects in COL1A2 are a cause of osteogenesis imperfecta type 1 (OI1). A dominantly inherited connective tissue disorder characterized by bone fragility and blue sclerae. Osteogenesis imperfecta type 1 is non-deforming with normal height or mild short stature, and no dentinogenesis imperfecta. Defects in COL1A2 are a cause of osteogenesis imperfecta type 2 (OI2); also known as osteogenesis imperfecta congenita (OIC) or lethal perinatal. A connective tissue disorder characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency. Defects in COL1A2 are the cause of Ehlers-Danlos syndrome autosomal recessive cardiac valvular form (EDSCV). A connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. In addition to joint laxity, skin hyperextensibility and friability, and abnormal scar formation, patients have mitral valve prolapse and insufficiency, mitral regurgitation, and aortic insufficiency. Defects in COL1A2 are a cause of osteogenesis imperfecta type 3 (OI3). A connective tissue disorder characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta. Defects in COL1A2 are a cause of osteogenesis imperfecta type 4 (OI4); also known as osteogenesis imperfecta with normal sclerae. A connective tissue disorder characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta. A chromosomal aberration involving COL1A2 may be a cause of lipoblastomas, which are benign tumors resulting from transformation of adipocytes, usually diagnosed in children. Translocation t(7;8)(p22;q13) with PLAG1. Belongs to the fibrillar collagen family. Protein type: Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 7q22.1. Cellular Component: extracellular matrix; extracellular space; endoplasmic reticulum lumen; extracellular region; collagen type I. Molecular Function: protein binding, bridging; identical protein binding; protein binding; metal ion binding; extracellular matrix structural constituent; platelet-derived growth factor binding; SMAD binding. Biological Process: odontogenesis; extracellular matrix disassembly; receptor-mediated endocytosis; platelet activation; blood vessel development; collagen catabolic process; extracellular matrix organization and biogenesis; collagen fibril organization; skin morphogenesis; transforming growth factor beta receptor signaling pathway; regulation of blood pressure; blood coagulation; leukocyte migration; skeletal development; Rho protein signal transduction. Disease: Ehlers-danlos Syndrome, Type Vii, Autosomal Dominant; Ehlers-danlos Syndrome, Autosomal Recessive, Cardiac Valvular Form; Osteogenesis Imperfecta, Type Ii; Osteogenesis Imperfecta, Type Iii; Osteoporosis; Osteogenesis Imperfecta, Type Iv

0.01 mg

140 USD

0.05 mg

255

0.1 mg

390

0.2 mg

480

0.5 mg

935

1 mg

1380